Second-line options for refractory steroid-sensitive and -resistant nephrotic syndrome

Expert Review of Clinical Pharmacology

Volumn 3, Issue 4, 2010, Pages 527-537

  Oh, Jun ^a   Kemper, Markus J ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

focal segmental glomerulosclerosis; FSGS; immunosuppression; MCNS; minimal change glomerulonephritis; nephrotic syndrome; steroid resistant; steroid sensitive

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BASILIXIMAB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALACTOSE; HERBACEOUS AGENT; INTERLEUKIN 2; LEVAMISOLE; METHYLPREDNISOLONE; MIZORIBINE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; VINCRISTINE;

ANTHELMINTIC ACTIVITY; B LYMPHOCYTE; BONE MARROW SUPPRESSION; CHINESE HERB; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOCAL GLOMERULOSCLEROSIS; GASTROINTESTINAL SYMPTOM; GENETIC SCREENING; GINGIVA HYPERPLASIA; GONADAL DISEASE; HEMORRHAGIC CYSTITIS; HUMAN; HYPERTENSION; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LEUKOPENIA; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MALIGNANT TRANSFORMATION; NEPHROTIC SYNDROME; NEPHROTOXICITY; NEUTROPENIA; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROSPECTIVE STUDY; REFRACTORY STEROID RESISTANT NEPHROTIC SYNDROME; REFRACTORY STEROID SENSITIVE NEPHROTIC SYNDROME; RELAPSE; REVIEW; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 77954896137     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.10.31     Document Type: Review

References (104)

1. Murnaghan K, Vasmant D, Bensman A. Pulse methylprednisolone therapy in severe idiopathic childhood nephrotic syndrome. Acta Paediatr. Scand. 73(6), 733-739 (1984).
2. Hodson EM, Alexander SI. Evaluation and management of steroid-sensitive nephrotic syndrome. Curr. Opin. Pediatr. 20(2), 145-150 (2008).
3. International Study of Kidney Diseases in Children. Early identification of frequent relapsers among children with minimal change nephrotic syndrome. J. Pediatr. 101(4), 514-518 (1982).
4. Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft fur Padiatrische Nephrologie. Arch. Dis. Child. 62(11), 1102-1106 (1987).
5. Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Lancet 1(8582), 380-383 (1988).
6. Niaudet P. Long-term outcome of children with steroid-sensitive idiopathic nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 4(10), 1547-1548 (2009).
7. Tanphaichitr P, Tanphaichitr D, Sureeratanan J, Chatasingh S. Treatment of nephrotic syndrome with levamisole. J. Pediatr. 96(3 Pt 1), 490-493 (1980).
8. Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. British Association for Paediatric Nephrology. Lancet 337(8757), 1555-1557 (1991).
9. Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst. Rev. (1), CD002290 (2008).
10. Kemper MJ, Amon O, Timmermann K, Altrogge H, Muller-Wiefel DE. [The treatment with levamisole of frequently recurring steroid-sensitive idiopathic nephrotic syndrome in children]. Dtsch. Med. Wochenschr. 123(9), 239-243 (1998).
11. International Study of Kidney Diseases in Children. Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Lancet 2(7878), 423-427 (1974).
12. Kemper MJ, Altrogge H, Ludwig K, Timmermann K, Mueller-Wiefel DE. Unfavorable response to cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr. Nephrol. 14(8-9), 772-775 (2000).
13. Ueda N, Kuno K, Ito S. Eight and 12 week courses of cyclophosphamide in nephrotic syndrome. Arch. Dis. Child. 65(10), 1147-1150 (1990).
14. Vester U, Kranz B, Zimmermann S, Buscher R, Hoyer PF. The response to cyclophosphamide in steroid-sensitive nephrotic syndrome is influenced by polymorphic expression of glutathion-S- transferases-M1 and -P1. Pediatr. Nephrol. 20(4), 478-481 (2005).
15. Sharda SV, Gulati S, Tripathi G et al. Do glutathione-S-transferase polymorphisms influence response to intravenous cyclophosphamide therapy in idiopathic nephrotic syndrome? Pediatr. Nephrol. 23(11), 2001-2006 (2008).
16. Kyrieleis HA, Levtchenko EN, Wetzels JF. Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome. Am. J. Kidney Dis. 49 (5), 592-597 (2007).
17. Prasad N, Gulati S, Sharma RK, Singh U, Ahmed M. Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatr. Nephrol. 19(5), 494-498 (2004).
18. Gauthier B, Trachtman H. Pharmacological treatment of nephrotic syndrome. Drugs Today 35(1), 13-26 (1999).
19. Neuhaus TJ, Fay J, Dillon MJ, Trompeter RS, Barratt TM. Alternative treatment to corticosteroids in steroid sensitive idiopathic nephrotic syndrome. Arch. Dis. Child. 71(6), 522-526 (1994).
20. Ueda N, Takahashi K, Akioka Y, Morooka M, Ogawa A, Tsuzuki K. Beneficial effect of chlorambucil in steroid-dependent and cyclophosphamide-resistant minimal change nephrotic syndrome. J. Nephrol. 22(5), 610-615 (2009).
21. Kemper MJ, Kuwertz-Broeking E, Bulla M, Mueller-Wiefel DE, Neuhaus TJ. Recurrence of severe steroid dependency in cyclosporin a-treated childhood idiopathic nephrotic syndrome. Nephrol. Dial. Transplant. 19(5), 1136-1141 (2004).
22. Ruth EM, Kemper MJ, Leumann EP, Laube GF, Neuhaus TJ. Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J. Pediatr. 147(2), 202-207 (2005).
23. Kyrieleis HA, Lowik MM, Pronk I et al. Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin. J. Am. Soc. Nephrol. 4(10), 1593-1600 (2009).
24. Machardy N, Miles PV, Massengill SF et al. Management patterns of childhood- onset nephrotic syndrome. Pediatr. Nephrol. 24(11), 2193-2201 (2009).
25. Hulton SA, Neuhaus TJ, Dillon MJ, Barratt TM. Long-term cyclosporin a treatment of minimal-change nephrotic syndrome of childhood. Pediatr. Nephrol. 8(4), 401-403 (1994).
26. Cattran DC, Alexopoulos E, Heering P et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int. 72(12), 1429-1447 (2007).
27. Nozu K, Iijima K, Sakaeda T et al. Cyclosporin a absorption profiles in children with nephrotic syndrome. Pediatr. Nephrol. 20(7), 910-913 (2005).
28. Sumegi V, Haszon I, Bereczki C, Papp F, Turi S. Long-term follow-up after cyclophosphamide and cyclosporine-A therapy in steroid-dependent and -resistant nephrotic syndrome. Pediatr. Nephrol. 23(7), 1085-1092 (2008).
29. Niaudet P. Comparison of cyclosporin and chlorambucil in the treatment of steroid- dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr. Nephrol. 6(1), 1-3 (1992).
30. Ponticelli C, Edefonti A, Ghio L et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol. Dial. Transplant. 8(12), 1326-1332 (1993).
31. Hulton SA, Jadresic L, Shah V, Trompeter RS, Dillon MJ, Barratt TM. Effect of cyclosporin a on glomerular filtration rate in children with minimal change nephrotic syndrome. Pediatr. Nephrol. 8(4), 404-407 (1994).
32. Kengne-Wafo S, Massella L, Diomedi- Camassei F et al. Risk factors for cyclosporin a nephrotoxicity in children with steroid- dependant nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 4(9), 1409-1416 (2009).
33. Fujinaga S, Kaneko K, Muto T, Ohtomo Y, Murakami H, Yamashiro Y. Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome. Arch. Dis. Child. 91(8), 666-670 (2006).
34. Sinha MD, Macleod R, Rigby E, Clark AG. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol. Dial. Transplant. 21(7), 1848-1854 (2006).
35. Dotsch J, Dittrich K, Plank C, Rascher W. Is tacrolimus for childhood steroid- dependent nephrotic syndrome better than ciclosporin A? Nephrol. Dial. Transplant. 21(7), 1761-1763 (2006).
36. Dittrich K, Knerr I, Rascher W, Dotsch J. Transient insulin-dependent diabetes mellitus in children with steroid-dependent idiopathic nephrotic syndrome during tacrolimus treatment. Pediatr. Nephrol. 21(7), 958-961 (2006).
37. Westhoff TH, Van Der Giet M. Tacrolimus in the treatment of idiopathic nephrotic syndrome. Expert Opin. Investig. Drugs 16(7), 1099-1110 (2007).
38. Bagga A, Hari P, Moudgil A, Jordan SC. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am. J. Kidney Dis. 42(6), 1114-1120 (2003).
39. Gellermann J, Querfeld U. Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr. Nephrol. 19(1), 101-104 (2004).
40. Hogg RJ, Fitzgibbons L, Bruick J et al. Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the southwest pediatric nephrology study group. Clin. J. Am. Soc. Nephrol. 1(6), 1173-1178 (2006).
41. Fujinaga S, Ohtomo Y, Hirano D et al. Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center. Clin. Nephrol. 72(4), 268-273 (2009).
42. Ulinski T, Dubourg L, Said MH, Parchoux B, Ranchin B, Cochat P. Switch from cyclosporine a to mycophenolate mofetil in nephrotic children. Pediatr. Nephrol. 20(4), 482-485 (2005).
43. Dorresteijn EM, Kist-Van Holthe JE, Levtchenko EN, Nauta J, Hop WC, Van Der Heijden AJ. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr. Nephrol. 23(11), 2013-2020 (2008).
44. Mendizabal S, Zamora I, Berbel O, Sanahuja MJ, Fuentes J, Simon J. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatr. Nephrol. 20(7), 914-919 (2005).
45. Kawasaki Y, Suzuki J, Takahashi A, Isome M, Nozawa R, Suzuki H. Mizoribine oral pulse therapy for steroid-dependent nephrotic syndrome. Pediatr. Nephrol. 20(1), 96-98 (2005).
46. Kemper MJ, Meyer-Jark T, Lilova M, Mueller-Wiefel DE. Combined T- and B-cell activation in childhood steroid- sensitive nephrotic syndrome. Clin. Nephrol. 60(4), 242-247 (2003).
47. Guigonis V, Dallocchio A, Baudouin V et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr. Nephrol. 23(8), 1269-1279 (2008).
48. Kamei K, Ito S, Nozu K et al. Single dose of rituximab for refractory steroid- dependent nephrotic syndrome in children. Pediatr. Nephrol. 24(7), 1321-1328 (2009).
49. Prytula A, Iijima K, Kamei K et al. Rituximab in refractory nephrotic syndrome. Pediatr. Nephrol. 25(3), 461-468 (2009).
50. Kemper MJ, Moeller C, Rink N, Van Husen M, Mueller-Wiefel DE. Treatment of refractory steroid sensitive nephrotic syndrome with rituximab. Pediatr. Nephrol. 22, 1445 (2007).
51. Chaumais MC, Garnier A, Chalard F et al. Fatal pulmonary fibrosis after rituximab administration. Pediatr. Nephrol. 24(9), 1753-1755 (2009).
52. Park SS, Hahn WH, Kim SD, Cho BS. Remission of refractory minimal change nephrotic syndrome after basiliximab therapy. Pediatr. Nephrol. 24(7), 1403-1407 (2009).
53. Francois H, Daugas E, Bensman A, Ronco P. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am. J. Kidney Dis. 49(1), 158-161 (2007).
54. Raveh D, Shemesh O, Ashkenazi YJ, Winkler R, Barak V. Tumor necrosis factor-alpha blocking agent as a treatment for nephrotic syndrome. Pediatr. Nephrol. 19(11), 1281-1284 (2004).
55. Kausman JY, Yin L, Jones CL, Johnstone L, Powell HR. Vincristine treatment in steroid-dependent nephrotic syndrome. Pediatr. Nephrol. 20(10), 1416-1419 (2005). (Pubitemid 41403415)
56. Krishnan RG, Coulthard MG, Moghal NE. Is there a role for vincristine in nephrotic syndrome? Pediatr. Nephrol. 21(4), 597 (2006).
57. Wei J. [Treatment of 100 children with infantile nephrotic syndrome by integrated traditional chinese medicine and western medicine]. Zhongguo Zhong Xi Yi Jie He Za Zhi 12(8), 465-468, 452 (1992).
58. Wu HM, Tang JL, Sha ZH, Cao L, Li YP. Interventions for preventing infection in nephrotic syndrome. Cochrane Database Syst. Rev. (2), CD003964 (2004).
59. Vehaskari VM. Treatment practices of FSGS among north american pediatric nephrologists. Pediatr. Nephrol. 13(4), 301-303 (1999).
60. Gipson DS, Chin H, Presler TP et al. Differential risk of remission and ESRD in childhood FSGS. Pediatr. Nephrol. 21(3), 344-349 (2006).
61. Bhimma R, Adhikari M, Asharam K. Steroid-resistant nephrotic syndrome: the influence of race on cyclophosphamide sensitivity. Pediatr. Nephrol. 21(12), 1847-1853 (2006).
62. El-Husseini A, El-Basuony F, Mahmoud I et al. Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience. Nephrol. Dial. Transplant. 20(11), 2433-2438 (2005).
63. Hari P, Bagga A, Jindal N, Srivastava RN. Treatment of focal glomerulosclerosis with pulse steroids and oral cyclophosphamide. Pediatr. Nephrol. 16(11), 901-905 (2001).
64. Ehrich JH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellermann J. Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol. Dial. Transplant. 22(8), 2183-2193 (2007).
65. Plank C, Kalb V, Hinkes B, Hildebrandt F, Gefeller O, Rascher W. Cyclosporin a is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the arbeitsgemeinschaft fur Padiatrische Nephrologie. Pediatr. Nephrol. 23(9), 1483-1493 (2008).
66. Shenoy M, Plant ND, Lewis MA, Bradbury MG, Lennon R, Webb NJ. Intravenous methylprednisolone in idiopathic childhood nephrotic syndrome Pediatr. Nephrol. 25(5), 899-903 (2010).
67. Meyrier AY. Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis? Kidney Int. 76(5), 487-491 (2009).
68. Faul C, Donnelly M, Merscher-Gomez S et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat. Med. 14(9), 931-938 (2008).
69. Pena A, Bravo J, Melgosa M et al. Steroid-resistant nephrotic syndrome: Long-term evolution after sequential therapy. Pediatr. Nephrol. 22(11), 1875-1880 (2007).
70. Ponticelli C, Rizzoni G, Edefonti A et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 43(6), 1377-1384 (1993).
71. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J. Am. Soc. Nephrol. 7(1), 56-63 (1996).
72. Colquitt JL, Kirby J, Green C, Cooper K, Trompeter RS. The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review. Health Technol. Assess. 11(21), 1-93 (2007).
73. Garin EH, Orak JK, Hiott KL, Sutherland SE. Cyclosporine therapy for steroid- resistant nephrotic syndrome. A controlled study. Am. J. Dis. Child. 142(9), 985-988 (1988).
74. Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French society of pediatric nephrology. J. Pediatr. 125(6 Pt 1), 981-986 (1994).
75. Ingulli E, Singh A, Baqi N, Ahmad H, Moazami S, Tejani A. Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomerulosclerosis. J. Am. Soc. Nephrol. 5(10), 1820-1825 (1995).
76. Hamasaki Y, Yoshikawa N, Hattori S et al. Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. Pediatr. Nephrol. 24(11), 2177-2185 (2009).
77. Segarra A, Vila J, Pou L et al. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol. Dial. Transplant. 17(4), 655-662 (2002).
78. Duncan N, Dhaygude A, Owen J et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol. Dial. Transplant. 19(12), 3062-3067 (2004).
79. Li X, Li H, Ye H et al. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. Am. J. Kidney Dis. 54(1), 51-58 (2009).
80. Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr. Nephrol. 19(3), 281-287 (2004).
81. Gulati S, Prasad N, Sharma RK, Kumar A, Gupta A, Baburaj VP. Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children. Nephrol. Dial. Transplant. 23(3), 910-913 (2008).
82. Butani L, Ramsamooj R. Experience with tacrolimus in children with steroid-resistant nephrotic syndrome. Pediatr. Nephrol. 24(8), 1517-1523 (2009).
83. Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am. J. Kidney Dis. 53(5), 760-769 (2009).
84. Buyukcelik M, Cengiz N, Dursun H et al. Intravenous pulse cyclophosphamide therapy in focal segmental glomerulosclerosis. Clin. Nephrol. 65(1), 7-12 (2006).
85. Rennert WP, Kala UK, Jacobs D, Goetsch S, Verhaart S. Pulse cyclophosphamide for steroid-resistant focal segmental glomerulosclerosis. Pediatr. Nephrol. 13(2), 113-116 (1999).
86. Gulati S, Kher V. Intravenous pulse cyclophosphamide - a new regime for steroid resistant focal segmental glomerulosclerosis. Indian Pediatr. 37(2), 141-148 (2000).
87. Al Salloum AA. Pulse cyclophosphamide therapy for steroid-resistant focal segmental glomerulosclerosis in children. Ann. Saudi Med. 24(1), 27-30 (2004).
88. Abeyagunawardena AS, Sebire NJ, Risdon RA et al. Predictors of long-term outcome of children with idiopathic focal segmental glomerulosclerosis. Pediatr. Nephrol. 22(2), 215-221 (2007).
89. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the international study of kidney disease in children. Pediatr. Nephrol. 10(5), 590-593 (1996).
90. Cattran DC, Wang MM, Appel G, Matalon A, Briggs W. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin. Nephrol. 62(6), 405-411 (2004).
91. El-Reshaid K, El-Reshaid W, Madda J. Combination of immunosuppressive agents in treatment of steroid-resistant minimal change disease and primary focal segmental glomerulosclerosis. Ren. Fail. 27(5), 523-530 (2005).
92. Montane B, Abitbol C, Chandar J, Strauss J, Zilleruelo G. Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr. Nephrol. 18(8), 772-777 (2003).
93. Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB. Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr. Nephrol. 18(8), 833-837 (2003).
94. Gellermann J, Querfeld U. Long-term outcome of idiopathic steroid resistant nephrotic syndrome-associated with focal segmental glomerulosclerosis: a single center study. Pediatr. Nephrol. 24, 1807 (2009).
95. Yabu JM, Ho B, Scandling JD, Vincenti F. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am. J. Transplant. 8(1), 222-227 (2008).
96. Nakayama M, Kamei K, Nozu K et al. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr. Nephrol. 23(3), 481-485 (2008).
97. Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N. Engl. J. Med. 356(26), 2751-2752 (2007).
98. Querfeld U, Kohl B, Fiehn W et al. Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome. Report of a prospective uncontrolled multicenter study. Pediatr. Nephrol. 13(1), 7-12 (1999).
99. De Smet E, Rioux JP, Ammann H, Deziel C, Querin S. FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. Nephrol. Dial. Transplant. 24(9), 2938-2940 (2009).
100. Fencl F, Simkova E, Vondrak K et al. Recurrence of nephrotic proteinuria in children with focal segmental glomerulosclerosis after renal transplantation treated with plasmapheresis and immunoadsorption: case reports. Transplant. Proc. 39(10), 3488-3490 (2007).
101. Cho ME, Hurley JK, Kopp JB. Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am. J. Kidney Dis. 49 (2), 310-317 (2007).
102. Tumlin JA, Miller D, Near M, Selvaraj S, Hennigar R, Guasch A. A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 1(1), 109-116 (2006).
103. Tsagalis G, Psimenou E, Iliadis A, Nakopoulou L, Laggouranis A. Rapamycin for focal segmental glomerulosclerosis: a report of 3 cases. Am. J. Kidney Dis. 54(2), 340-344 (2009).
104. International Study of Kidney Diseases in Children. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. Kidney Int. 13(2), 159-165 (1978).